Concise review: Mesenchymal stromal cells: Potential for cardiovascular repair

Peter J. Psaltis, Andrew C W Zannettino, Stephen G. Worthley, Stan Gronthos

Research output: Contribution to journalReview article

273 Citations (Scopus)

Abstract

Cellular therapy for cardiovascular disease heralds an exciting frontier of research. Mesenchymal stromal cells (MSCs) are present in adult tissues, including bone marrow and adipose, from which they can be easily isolated and cultured ex vivo. Although traditional isolation of these cells by plastic adherence results in a heterogeneous composite of mature and immature cell types, MSCs do possess plasticity of differentiation and under appropriate in vitro culture conditions can be modified to adopt cardiomyocyte and vascular cell phenotypic characteristics. In vivo preclinical studies have demonstrated their capacity to facilitate both myocardial repair and neovascularization in models of cardiac injury. The mechanisms underlying these effects appear to be mediated predominantly through indirect paracrine actions, rather than direct regeneration of endogenous cells by transdifferentiation, especially because current transplantation strategies achieve only modest engraftment of cells in the host myocardium. Currently, published clinical trial experience of MSCs as cardiac therapy is limited, and the outcomes of ongoing studies are keenly anticipated. Of relevance to clinical application is the fact that MSCs are relatively immunoprivileged, potentially enabling their allogeneic therapeutic use, although this too requires further investigation. Overall, MSCs are an attractive adult-derived cell population for cardiovascular repair; however, research is still required at both basic and clinical levels to resolve critical areas of uncertainty and to ensure continued development in cell culture engineering and cell transplantation technology.

LanguageEnglish
Pages2201-2210
Number of pages10
JournalStem Cells
Volume26
Issue number9
DOIs
Publication statusPublished - 1 Sep 2008

Keywords

  • Angiogenesis
  • Cardiac diseases
  • Mesenchymal stromal cells
  • Myogenesis
  • Tissue engineering

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Psaltis, Peter J. ; Zannettino, Andrew C W ; Worthley, Stephen G. ; Gronthos, Stan. / Concise review : Mesenchymal stromal cells: Potential for cardiovascular repair. In: Stem Cells. 2008 ; Vol. 26, No. 9. pp. 2201-2210.
@article{ead74168e05a4910ac9547d88d44e79d,
title = "Concise review: Mesenchymal stromal cells: Potential for cardiovascular repair",
abstract = "Cellular therapy for cardiovascular disease heralds an exciting frontier of research. Mesenchymal stromal cells (MSCs) are present in adult tissues, including bone marrow and adipose, from which they can be easily isolated and cultured ex vivo. Although traditional isolation of these cells by plastic adherence results in a heterogeneous composite of mature and immature cell types, MSCs do possess plasticity of differentiation and under appropriate in vitro culture conditions can be modified to adopt cardiomyocyte and vascular cell phenotypic characteristics. In vivo preclinical studies have demonstrated their capacity to facilitate both myocardial repair and neovascularization in models of cardiac injury. The mechanisms underlying these effects appear to be mediated predominantly through indirect paracrine actions, rather than direct regeneration of endogenous cells by transdifferentiation, especially because current transplantation strategies achieve only modest engraftment of cells in the host myocardium. Currently, published clinical trial experience of MSCs as cardiac therapy is limited, and the outcomes of ongoing studies are keenly anticipated. Of relevance to clinical application is the fact that MSCs are relatively immunoprivileged, potentially enabling their allogeneic therapeutic use, although this too requires further investigation. Overall, MSCs are an attractive adult-derived cell population for cardiovascular repair; however, research is still required at both basic and clinical levels to resolve critical areas of uncertainty and to ensure continued development in cell culture engineering and cell transplantation technology.",
keywords = "Angiogenesis, Cardiac diseases, Mesenchymal stromal cells, Myogenesis, Tissue engineering",
author = "Psaltis, {Peter J.} and Zannettino, {Andrew C W} and Worthley, {Stephen G.} and Stan Gronthos",
year = "2008",
month = "9",
day = "1",
doi = "10.1634/stemcells.2008-0428",
language = "English",
volume = "26",
pages = "2201--2210",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "9",

}

Concise review : Mesenchymal stromal cells: Potential for cardiovascular repair. / Psaltis, Peter J.; Zannettino, Andrew C W; Worthley, Stephen G.; Gronthos, Stan.

In: Stem Cells, Vol. 26, No. 9, 01.09.2008, p. 2201-2210.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Concise review

T2 - Stem Cells

AU - Psaltis, Peter J.

AU - Zannettino, Andrew C W

AU - Worthley, Stephen G.

AU - Gronthos, Stan

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Cellular therapy for cardiovascular disease heralds an exciting frontier of research. Mesenchymal stromal cells (MSCs) are present in adult tissues, including bone marrow and adipose, from which they can be easily isolated and cultured ex vivo. Although traditional isolation of these cells by plastic adherence results in a heterogeneous composite of mature and immature cell types, MSCs do possess plasticity of differentiation and under appropriate in vitro culture conditions can be modified to adopt cardiomyocyte and vascular cell phenotypic characteristics. In vivo preclinical studies have demonstrated their capacity to facilitate both myocardial repair and neovascularization in models of cardiac injury. The mechanisms underlying these effects appear to be mediated predominantly through indirect paracrine actions, rather than direct regeneration of endogenous cells by transdifferentiation, especially because current transplantation strategies achieve only modest engraftment of cells in the host myocardium. Currently, published clinical trial experience of MSCs as cardiac therapy is limited, and the outcomes of ongoing studies are keenly anticipated. Of relevance to clinical application is the fact that MSCs are relatively immunoprivileged, potentially enabling their allogeneic therapeutic use, although this too requires further investigation. Overall, MSCs are an attractive adult-derived cell population for cardiovascular repair; however, research is still required at both basic and clinical levels to resolve critical areas of uncertainty and to ensure continued development in cell culture engineering and cell transplantation technology.

AB - Cellular therapy for cardiovascular disease heralds an exciting frontier of research. Mesenchymal stromal cells (MSCs) are present in adult tissues, including bone marrow and adipose, from which they can be easily isolated and cultured ex vivo. Although traditional isolation of these cells by plastic adherence results in a heterogeneous composite of mature and immature cell types, MSCs do possess plasticity of differentiation and under appropriate in vitro culture conditions can be modified to adopt cardiomyocyte and vascular cell phenotypic characteristics. In vivo preclinical studies have demonstrated their capacity to facilitate both myocardial repair and neovascularization in models of cardiac injury. The mechanisms underlying these effects appear to be mediated predominantly through indirect paracrine actions, rather than direct regeneration of endogenous cells by transdifferentiation, especially because current transplantation strategies achieve only modest engraftment of cells in the host myocardium. Currently, published clinical trial experience of MSCs as cardiac therapy is limited, and the outcomes of ongoing studies are keenly anticipated. Of relevance to clinical application is the fact that MSCs are relatively immunoprivileged, potentially enabling their allogeneic therapeutic use, although this too requires further investigation. Overall, MSCs are an attractive adult-derived cell population for cardiovascular repair; however, research is still required at both basic and clinical levels to resolve critical areas of uncertainty and to ensure continued development in cell culture engineering and cell transplantation technology.

KW - Angiogenesis

KW - Cardiac diseases

KW - Mesenchymal stromal cells

KW - Myogenesis

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=55049099231&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2008-0428

DO - 10.1634/stemcells.2008-0428

M3 - Review article

VL - 26

SP - 2201

EP - 2210

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 9

ER -